Innate Pharma Stock

Equities

IPH

FR0010331421

Biotechnology & Medical Research

Real-time Euronext Paris 10:04:55 2024-06-17 EDT 5-day change 1st Jan Change
2.04 EUR -4.00% Intraday chart for Innate Pharma -16.19% -21.95%

Financials

Sales 2024 * 50.51M 54.13M 74.41M Sales 2025 * 70.33M 75.37M 104M Capitalization 172M 184M 253M
Net income 2024 * -23M -24.65M -33.88M Net income 2025 * -25M -26.79M -36.83M EV / Sales 2024 * 1.94 x
Net cash position 2024 * 73.78M 79.07M 109M Net cash position 2025 * 131M 140M 193M EV / Sales 2025 * 0.58 x
P/E ratio 2024 *
-17 x
P/E ratio 2025 *
3.51 x
Employees 179
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Innate Pharma

1 day-3.76%
1 week-16.19%
Current month-19.17%
1 month-15.15%
3 months-6.62%
6 months-12.79%
Current year-21.95%
More quotes
1 week
1.89
Extreme 1.89
2.45
1 month
1.89
Extreme 1.89
2.79
Current year
1.89
Extreme 1.89
2.80
1 year
1.89
Extreme 1.89
3.10
3 years
1.89
Extreme 1.89
8.30
5 years
1.89
Extreme 1.89
8.30
10 years
1.89
Extreme 1.89
17.85
More quotes
Managers TitleAgeSince
Founder 60 99-09-22
Chief Executive Officer 62 99-09-22
Director of Finance/CFO 49 21-03-31
Members of the board TitleAgeSince
Chief Executive Officer 62 99-09-22
Director/Board Member 72 07-06-25
Director/Board Member 54 10-05-24
More insiders
Date Price Change Volume
24-06-17 2.04 -4.00% 221 929
24-06-14 2.125 -3.63% 200,735
24-06-13 2.205 -2.43% 54,998
24-06-12 2.26 -2.38% 55,468
24-06-11 2.315 -5.12% 135,906

Real-time Euronext Paris, June 17, 2024 at 10:04 am

More quotes
Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows: - revenues from collaboration and licensing agreements (84.2%); - government financing for research expenditure (15.8%). At the end of 2023, the company had a portfolio of 7 products in clinical development, including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphomas and IPH5201 for the treatment of cancer) and 4 in phase I (IPH5301 for the treatment of solid tumours, IPH6101 for the treatment of relapsed or refractory acute myeloid leukaemia, IPH6401 for the treatment of multiple myeloma and IPH6501 for the treatment of non-Hodgkin lymphoma).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.125 EUR
Average target price
6.475 EUR
Spread / Average Target
+204.71%
Consensus